ZWJ Investment Counsel’s Alexion Pharmaceuticals ALXN Stock Holding History

ZWJ Investment Counsel’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-71,977	Closed	-$9.43M	–	157
2019 Q2	$9.43M	Buy	71,977 +15,177	+27%	+$1.96M	0.74%	48
2019 Q1	$7.68M	Buy	56,800 +6,185	+12%	+$769K	0.63%	49
2018 Q4	$4.93M	Sell	50,615 -12,987	-20%	-$1.54M	0.46%	56
2018 Q3	$8.84M	Buy	63,602 +433	+0.7%	+$54.3K	0.72%	47
2018 Q2	$7.84M	Buy	63,169 +1,751	+3%	+$205K	0.68%	50
2018 Q1	$6.85M	Buy	61,418 +2,373	+4%	+$284K	0.62%	52
2017 Q4	$7.06M	Sell	59,045 -24,003	-29%	-$2.92M	0.56%	49
2017 Q3	$11.7M	Buy	83,048 +20,721	+33%	+$2.82M	0.91%	43
2017 Q2	$7.58M	Buy	62,327 +60,206	+2,839%	+$7.01M	0.61%	49
2017 Q1	$257K	Buy	+2,121	New	+$273K	0.02%	270

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ZWJ Investment Counsel's ALXN Position: Q3 2019 in Review

ZWJ Investment Counsel sold out of Alexion Pharmaceuticals (ALXN) in Q3 2019, closing a stake of 71,977 shares — an estimated $9.43M sold.

ZWJ Investment Counsel first reported a position in ALXN in Q1 2017 and held it in 10 quarters. The position peaked at $11.7M in Q3 2017. 647 funds tracked by Wall St. Rank hold ALXN as of Q3 2019.

ZWJ Investment Counsel reported no remaining Alexion Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
ZWJ Investment Counsel sold 71,977 Alexion Pharmaceuticals shares in Q3 2019, an estimated $9.43M.
ZWJ Investment Counsel first reported a position in Alexion Pharmaceuticals in Q1 2017 and held it in 10 quarters.
ZWJ Investment Counsel's Alexion Pharmaceuticals position peaked at $11.7M in Q3 2017.
647 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2019.

Based on ZWJ Investment Counsel's 13F filing for Q3 2019, filed 22 Oct 2019.